NVIDIA Healthcare Global

Biofy

Real-time Analytics

Hospitals needed pathogen identification and antibiotic-resistance analysis much faster than five-day culture and antibiogram workflows, but CPU-bound genomic processing and limited AI expertise made it hard to turn sequencing data into timely treatment decisions.

100,000+ synthetic DNA sequences generated by the biology model
30x speedup including DNA sequencing and AI analysis
32x H100 Tensor Core GPUs used for training and serving
50% better performance with NVIDIA GPUs at up to half the cost of alternative cloud providers

Reported impact

Business outcome

Biofy reduced treatment recommendation time from roughly five days to about four hours, improved performance by 50 percent at up to half the cost of alternative cloud providers, raised diagnostic accuracy to 95–97 percent, and has already supported several thousand tests while reportedly helping save more than a hundred lives.

  • Cost Reduction
  • Productivity Improvement
  • Risk Reduction

Solution

Biofy built a cloud-native genomic diagnostics pipeline on Oracle Cloud Infrastructure and NVIDIA acceleration to compress multi-day infectious-disease workflows into hours. Full-genome DNA sequences are assembled with NVIDIA-accelerated algorithms, embedded as vectors, and matched against large microbial-genome and resistance-marker databases. Abby, Biofy’s recommendation engine, then analyzes the detected resistance genes and suggests the most effective antibiotics or treatment path for the specific infection. Under the hood, Biofy uses NVIDIA RAPIDS, NVIDIA cuDF, NVIDIA cuML, CUDA-accelerated libraries, and 32 H100 Tensor Core GPUs to run large-scale DNA matrix operations, model training, and inference. Oracle Autonomous AI Database and Oracle AI Vector Search store and retrieve genomic vectors, while the platform also generates more than 100,000 synthetic DNA sequences to keep resistance models current as bacteria mutate.

Data flow

Hospitals sequence bacterial DNA, OCI-hosted NVIDIA pipelines assemble full genomes and convert them into vectors, Oracle stores and searches those vectors against microbial and resistance databases, and Abby returns pathogen identification plus antibiotic recommendations into the clinical workflow.

Solution architecture

9 components · 3 layers
  1. Compute
    • Oracle Cloud Infrastructure Hosts Biofy’s cloud-native genomic assembly, vector search, model training, and inference pipeline.
    • NVIDIA RAPIDS Accelerates the GPU data-processing layer for large genomic workloads.
    • NVIDIA cuDF Processes large volumes of DNA data inside the RAPIDS-based pipeline.
    • NVIDIA cuML Corrects errors present in DNA as part of the genomic analysis workflow.
    • NVIDIA CUDA-accelerated libraries Speed up DNA matrix operations and embeddings on GPUs through OCI.
    • H100 Tensor Core GPUs Provide the large-scale GPU training and serving capacity for genomic and LLM-based models.
  2. Storage
    • Oracle Autonomous AI Database Stores genomic vectors for downstream inference and retrieval.
  3. Serving
    • Abby Analyzes resistance genes and recommends the best-fit antibiotic treatment for each infection.
    • Oracle AI Vector Search Retrieves microbial-genome and resistance-marker vectors quickly and cost efficiently.

Architecture clues

  • Biofy’s Llama 3-based biology model continuously generates more than 100,000 synthetic DNA sequences to anticipate new resistance variants.
  • Oracle is evaluating NVIDIA cuVS to accelerate vector search and index builds on Oracle Database 26ai.
  • The platform assembles full bacterial genomes, embeds them as vectors, and matches them against microbial genomes and resistance markers.

Evidence from the source

Biofy implemented a cloud-native pipeline that runs NVIDIA-accelerated algorithms to assemble full bacterial genomes, embed them as vectors, and match these vectors against a larger database of microbial genomes and resistance markers.
Improved performance by 50% with NVIDIA GPUs, at up to half the cost of alternative cloud providers.
Increased diagnostic accuracy to 95–97% compared with traditional laboratory tests (PCR + antibiogram) that reach 80% accuracy with 33% failure rate.
Reduced time to treatment recommendation from five days to four hours, including DNA sequencing and AI analysis—a 30x speedup.
The storing of genomic vectors was done in Oracle Autonomous AI Database with Oracle AI Vector Search to keep model inference fast and cost efficient.
Transparency Evidence & methodology 100/100 reference value · 92% confidence · 2 sources

Review how this reference was scored and trace each normalized claim back to its documented source.

01

Scoring methodology

How scores are calculated

Customer Reference Value measures usefulness as a customer reference. Evidence Confidence measures the quality and traceability of available evidence, not independent verification.

Customer reference value100/100
  • Problem clarity20/20
    Measures whether the customer's operational problem is specific enough to compare.
  • Implementation depth25/25
    Rewards named components, data flow, integrations, and architecture detail.
  • Outcome specificity20/20
    Measures whether the reported benefit is concrete rather than a generic claim.
  • Quantified impact25/25
    4 metrics describe measurable impact.
  • Deployment scale10/10
    Rewards evidence of a live or scaled deployment and meaningful integration scope.
Evidence confidence92%
  • Source authority20/25
    The main evidence is an official vendor-published customer story.
  • Claim traceability23/25
    11 of 12 key fields link to a named source.
  • Direct evidence20/20
    5 direct source quotes retained.
  • Date provenance10/10
    The publication date comes from the source page or publisher.
  • Source transparency9/10
    2 source references document publisher, URL, authority, retrieval, and supported fields.
  • Implementation specificity10/10
    Rewards source-backed components, data flow, quantified impact, and a specific outcome.
02

Traceability

Sources & provenance

Field coverage shows which facts each source supports. Dates are shown only when documented by the source.

  1. NVIDIA

    Biofy customer story

    First-party
    https://www.nvidia.com/en-us/case-studies/biofy/
    Source type
    Vendor-published customer story
    Published
    Apr 23, 2026
    Supports
    • Customer
    • Business problem
    • Solution
    • Products
    • Solution components
    • Data flow
    • Integrations
    • technical area
    • use case category
    • Business outcome
    • outcome category
    • Metrics
    • Architecture
    • evidence quotes
    • Publication date
  2. LinkedIn

    Biofy | LinkedIn

    Independent secondary
    https://www.linkedin.com/company/biofytech

    Public company page lists company size 11-50 employees; page JSON-LD reports numberOfEmployees value 16.

    Source type
    Structured company profile
    Supports
    • Company size

Date evidence

  • Published on source page Apr 23, 2026 · NVIDIA · First-party
    Open date source
Not separately sourced Industry, Region. Treat these normalized attributes as lower-confidence until a dedicated source is added.